AAP
CARM

Ardsley Advisory Partners’s Carisma Therapeutics CARM Stock Holding History

Ardsley Advisory Partners’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,025
Closed -$21K – 153
2019
Q1 		$21K Buy
+1,025
New +$17.7K ﹤0.01% 131

Other funds holding CARM

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Ardsley Advisory Partners's CARM Position: Q2 2019 in Review

Ardsley Advisory Partners sold out of Carisma Therapeutics (CARM) in Q2 2019, closing a stake of 1,025 shares — an estimated $21K sold.

Ardsley Advisory Partners first reported a position in CARM in Q1 2019 and held it in 1 quarter. The position peaked at $21K in Q1 2019. 43 funds tracked by Wall St. Rank hold CARM as of Q2 2019.

  • Ardsley Advisory Partners reported no remaining Carisma Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 1,025 Carisma Therapeutics shares in Q2 2019, an estimated $21K.
  • Ardsley Advisory Partners first reported a position in Carisma Therapeutics in Q1 2019 and held it in 1 quarter.
  • Ardsley Advisory Partners's Carisma Therapeutics position peaked at $21K in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2019.

Based on Ardsley Advisory Partners's 13F filing for Q2 2019, filed 13 Aug 2019.